Cancer drug out-performs against Skin, Lung Cancer

Keytruda, bested the standard of care in advanced Melanoma, the deadly skin cancer, and showed promising results in Non-small cell Lung Cancer. Based on these data, Merck says it has filed an application with the FDA for Keytruda to be used in non-small cell lung cancer, and will soon file for it to be used as a first option in melanoma.“I think we are watching a revolutionary change in cancer therapy,” says Roger Perlmutter, Merck’s head of research and development. “Certainly the most important advance in my lifetime and maybe the most important advance since the introduction of radiotherapy.”